Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Current pharmaceutical design

• Publication date

  2009-05-01

• Fields of study

  Medicine, History

• Identifiers
  DOI 10.2174/138161209788168001PMID 19442174
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neuropsychiatric Involvement in Systemic Lupus Erythematosus

  2011cited by this paper
• Central nervous system abnormalities in fibromyalgia and chronic fatigue syndrome: new concepts in treatment.

  2008cited by this paper
• La introducción clínica de la iproniazida y la imipramina: medio siglo de terapéutica antidepresiva

  2008influential reference
• Neuropsychiatric involvement in systemic lupus erythematosus: current therapeutic approach.

  2008cited by this paper
• Half a century of antidepressant drugs: on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part II: tricyclics and tetracyclics.

  2008cited by this paper
• Designing new treatments for depression and anxiety.

  2008cited by this paper
• Historia de la Psicofarmacología. Tomo 3. La consolidación de la psicofarmacología como disciplina científica: aspectos ético-legales y perspectivas de futuro .

  2007cited by this paper
• Contribución de la iproniazida y la imipramina al desarrollo de la psiquiatría biológica: primeras hipótesis etiopatogénicas de los trastornos afectivos

  2007influential reference
• Half a century of antidepressant drugs: on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part I: monoamine oxidase inhibitors.

  2007influential reference
• Consecuencias socio-sanitarias de la introduccion clinica de los psicofarmacos

  2006cited by this paper
• History of the discovery and clinical introduction of chlorpromazine.

  2005cited by this paper
• Brofaromine — a review of its pharmacological properties and therapeutic use

  2005cited by this paper
• Melancholia in the Writing of a Sixteenth‐Century Spanish Nun

  2004cited by this paper
• La contribución de la reserpina al desarrollo de la psiquiatría y su papel en la investigación neurobiológica

  2004cited by this paper
• The early history of psychotherapeutic drugs

  2004cited by this paper
• Half a century since the clinical introduction of chlorpromazine and the birth of modern psychopharmacology.

  2004cited by this paper
• The new generation of antidepressants.

  2003cited by this paper
• Emil Fischer, His Personality, His Achievements, and His Scientific Progeny

  2002cited by this paper
• Aspectos históricos del descubrimiento y de la introducción clínica de la clorpromazina: medio siglo de psicofarmacología

  2002cited by this paper
• Pharmacotherapy of depression: a historical analysis

  2001cited by this paper
• Role of norepinephrine in depression.

  2000cited by this paper
• La "Década de oro" de la psicofarmacología (1950-1960): trascendencia histórica de la introducción clínica de los psicofármacos clásicos.

  2000cited by this paper
• Problems with currently available antidepressants.

  2000cited by this paper
• The rise of psychopharmacology and the story of the CINP

  2000cited by this paper
• A History of Psychiatry: From the Era of the Asylum to the Age of Prozac

  2000cited by this paper
• Fundamentos biológicos en psiquiatría

  1999cited by this paper
• The Rise of Psychopharmacology and the Story of CINP.

  1999cited by this paper
• The three faces of the antidepressants: a critical commentary on the clinical-economic context of diagnosis.

  1999cited by this paper
• A decade of antidepressant development: the SSRIs and beyond.

  1998cited by this paper
• The Antidepressant Era

  1998influential reference
• Monoamine Oxidase Inhibitors

  1996cited by this paper
• Moclobemide versus fluoxetine in the treatment of inpatients with major depression.

  1995cited by this paper
• Listening to Prozac

  1994cited by this paper
• Current advances and trends in the treatment of depression.

  1994cited by this paper
• The chemistry of conscious states

  1994cited by this paper
• A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia.

  1993cited by this paper
• A double‐blind trial of fluoxetine, 20 mg, and placebo in out‐patients with DSM‐III-R major depression and melancholia

  1993cited by this paper
• Fluoxetine in the treatment of inpatients with major depressions

  1993cited by this paper
• Invited ACNP Lecture. The early history of modern psychopharmacology.

  1991cited by this paper
• Brofaromine - a Selective, Reversible, and Short-Acting MAO-A Inhibitor: Review of the Pharmacological and Clinical Findings

  1991cited by this paper
• Efficacy of reversible inhibitors of monoamine oxidase‐A in various forms of depression

  1990cited by this paper
• Affective spectrum disorder: does antidepressant response identify a family of disorders with a common pathophysiology?

  1990cited by this paper
• How reserpine and chlorpromazine act: the impact of key discoveries on the history of psychopharmacology.

  1990cited by this paper
• Monoamine Oxidase Inhibitors in Depression: History and Mythology

  1990cited by this paper
• Recent developments in aluminum toxicology.

  1989cited by this paper
• A European Study of Views on the Use of Monoamine Oxidase Inhibitors

  1989cited by this paper
• The efficacy of fluoxetine as an antidepressant in the short and long term.

  1989cited by this paper
• Serotonin: history of a discovery.

  1988cited by this paper
• Drug Discovery: the Evolution of Modern Medicines.

  1987cited by this paper
• Overview: toward a dysregulation hypothesis of depression.

  1985cited by this paper
• Monoamine oxidase inhibitors

  1984cited by this paper
• The new generation of antidepressants.

  1983cited by this paper
• Fluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptors.

  1983cited by this paper
• The new generation of antidepressants.

  1983cited by this paper
• Adverse reactions in connection with zimeldine treatment — a review

  1983cited by this paper
• Psychopharmacology of Depression: A Guide for Drug Treatment

  1982cited by this paper
• Psychiatric Side Effects of Antihypertensive Drugs Other Than Reserpine

  1982cited by this paper
• Role of 5‐hydroxytryptaminergic and adrenergic mechanism in antagonism of reserpine‐induced hypothermia in mice

  1979cited by this paper
• Monitoring 5-hydroxytryptamine release in the brain of the freely moving unanaesthetized rat using in vivo voltammetry.

  1979cited by this paper
• Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant

  1979cited by this paper
• Immobility induced by forced swimming in rats: effects of agents which modify central catecholamine and serotonin activity.

  1979cited by this paper
• Mode of action of antidepressant drugs.

  1978cited by this paper
• Fading: a new cytofluorimetric measure quantifying serotonin in the presence of catecholamines at the cellular level in brain.

  1978cited by this paper
• Effect of 3-(p-trifluoromethylphenoxy). N. N. methyl-3-phenylpropylamine on the depletion of brain serotonin by 4-chloroamphetamine.

  1975cited by this paper
• EFFECT OF 3-(p-TRIFLUOROMETHYLPHENOXY)-N-METHYL-3-PHENYLPROPYLAMINE ON THE DEPLETION OF BRAIN SEROTONIN BY 4-CHLOROAMPHETAMINE

  1975cited by this paper
• dl-N-methyl-3-(o-methoxyphenoxy)-3-phenylpropylamine hydrochloride, Lilly 94939, a potent inhibitor for uptake of norepinephrine into rat brain synaptosomes and heart.

  1975cited by this paper
• A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine.

  1974cited by this paper
• The monoamine oxidase inhibitor, phenelzine, in the treatment of depressive -anxiety states. A controlled clinical trial.

  1973cited by this paper
• Kinetics of serotonin accumulation into synaptosomes of rat brain--effects of amphetamine and chloroamphetamines.

  1973cited by this paper
• Multiple forms of monoamine oxidase and their properties.

  1972cited by this paper
• Historia, límites y perspectivas de la quimioterapia moderna de las enfermedades mentales

  1972cited by this paper
• Multiple forms of monoamine oxidase and their properties.

  1972influential reference
• Depressions following reserpine: a reevaluation.

  1971cited by this paper
• Structural specificity for inhibition of [14C]‐5‐hydroxytryptamine uptake by cerebral slices

  1970cited by this paper
• Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect.

  1969cited by this paper
• Activity of antihistamines in laboratory antidepressant tests.

  1969cited by this paper
• Central and peripheral monoaminergic membrane‐pump blockade by some addictive analgesics and antihistamines

  1969cited by this paper
• Some observations upon a new inhibitor of monoamine oxidase in brain tissue.

  1968cited by this paper
• The effect of imipramine of central 5‐hydroxytryptamine neurons

  1968cited by this paper
• The Biochemistry of Affective Disorders

  1967influential reference
• 5-Hydroxytryptamine in the Hind-Brain of Depressive Suicides

  1967cited by this paper
• Norepinephrine metabolism and drugs used in the affective disorders: a possible mechanism of action.

  1967cited by this paper
• 5-hydroxyindole compounds in the cerebrospinal fluid of patients with psychiatric or neurological diseases.

  1966cited by this paper
• CLINICAL PHARMACOLOGY OF IMIPRAMINE AND RELATED ANTIDEPRESSANT COMPOUNDS.

  1965cited by this paper
• The catecholamine hypothesis of affective disorders: a review of supporting evidence.

  1965cited by this paper
• Tranylcypromine: A review

  1965cited by this paper
• Inhibition of Uptake of Tritiated-noradrenaline in the Intact Rat Brain by Imipramine and Structurally Related Compounds

  1964cited by this paper
• SOME PHARMACOLOGICAL EFFECTS OF DESMETHYLIMIPRAMINE (DMI).

  1964cited by this paper
• HYPERTENSIVE CRISIS DUE TO MONOAMINE-OXIDASE INHIBITORS.

  1963cited by this paper
• Tranylcypromine and Cheese

  1963cited by this paper
• TRANYLCYPROMINE AND CHEESE.

  1963cited by this paper
• Potentiation of the antidepressive effect of a monoamine-oxidase inhibitor by tryptophan.

  1963cited by this paper
• Interactions between reserpine, chlorpromazine, and imipramine

  1960cited by this paper
• The modern treatment of depressive disorders.

  1960cited by this paper
• Treatment of Depression by Drugs and Other Means

  1960cited by this paper
• A New Inhibitor of Serotonin Metabolism

  1959cited by this paper
• A Controlled Trial of Imipramine in Treatment of Depressive States

  1959cited by this paper
• [On the pharmacology of tofranil (N-(3-dimethylaminopropyl)-iminodibenzyl hydrochloride].

  1959cited by this paper
• Some Pharmacological Observations on Tranylcypromine (SKF trans-385); A Potent Inhibitor of Monoamine Oxidase.∗

  1959cited by this paper
• The treatment of depressive states with G 22355 (imipramine hydrochloride).

  1958cited by this paper

• Panax notoginseng flower extract ameliorates chronic unpredictable mild stress -induced depression-like behaviors in mice by reducing neuroinflammation

  2026cites this paper
• Neurochemical and Energetic Alterations in Depression: A Narrative Review of Potential PET Biomarkers

  2026cites this paper
• Phase-Transition Thermodynamics of Hydrazide Drugs: Isoniazid and Iproniazid

  2026cites this paper
• In silico investigation of ketamine and methylphenidate drug-drug conjugate for MDD and ADHD treatment using MD simulations and MMGBSA

  2025cites this paper
• "His Discovery Has Revolutionized Psychiatry; It Has Opened Vast Horizons": Ugo Cerletti, a Missing Nobel Prize Laureate?

  2025cites this paper
• Antidepressants and the endogenous opioid system.

  2025cites this paper
• Identification of the subventricular tegmental nucleus as brainstem reward center.

  2025cites this paper
• Effects of Selective Serotonin Reuptake Inhibitors (SSRI) on the Placenta†.

  2025cites this paper
• Did Serendipity Contribute to the Discovery of New Antidepressant Drugs? Historical Analysis Using Operational Criteria

  2025influential citation
• Structure-Guided Design of Novel 5-HT2A Partial Agonists as Psychedelic Analogues with Antidepressant Effects.

  2025cites this paper
• Antidepressant effects of fluoxetine: upregulation of connexin 36 and 43 in the hippocampus, prefrontal cortex, and amygdala

  2025cites this paper
• Evidence-based guidelines for the pharmacological treatment of migraine

  2025cites this paper
• Could antidepressants increase mood and immunity at the same time?

  2025cites this paper
• Antidepressant-like actions of lanifibranor and its related mechanisms in mouse models of depression: Involvement of hippocampal PPARα and BDNF.

  2025cites this paper
• Accurate determination of fluoxetine and its metabolites in Mediterranean mussel organs based on solid phase extraction clean-up and HPLC-HRMS.

  2025cites this paper
• All roads lead to glutamate: NMDA and AMPA receptors as targets for rapid-acting antidepressants.

  2025cites this paper
• Prevalence and Trends of Tricyclic Antidepressant Poisoning in Ilam: A Comparative Analysis

  2025cites this paper
• SSRI-Human Entanglements: On Becoming with Antidepressants

  2025cites this paper
• The Assessment of the Safety Profile of Selective Serotonin Reuptake Inhibitors Versus Other Antidepressants: Drug–Drug Interaction Insights from EudraVigilance

  2025cites this paper
• Ganoderma lucidum: An Emerging Nutritional Approach to Manage Depression

  2025cites this paper
• Current Progress in Targeted Pharmacotherapy to Treat Symptoms of Major Depressive Disorder: Moving From Broad-Spectrum Treatments to Precision Psychiatry.

  2025cites this paper
• Bioelectronic medicine: a new frontier for autonomic nervous system disorders

  2025cites this paper
• Nutraceuticals in the Treatment of Major Depressive Disorder

  2025cites this paper
• Leptin-dopamine interactions: unveiling the common link between type-2 diabetes and neuropsychiatric comorbidities.

  2025cites this paper
• From betel nuts to Cobenfy: how an ancient recreational drug gave rise to a new class of schizophrenia medications

  2025cites this paper
• Phase behavior and relative stability of iproniazid polymorphs

  2025cites this paper
• The Developmental Toxicity of Haloperidol on Zebrafish (Danio rerio) Embryos

  2025cites this paper
• Potential diagnostic markers and therapeutic targets for major depressive disorder based on bioinformatics analysis and molecular docking studies

  2025cites this paper
• Dihydropyrimidines Emerge as Promising Dual‐Acting Inhibitors Targeting Acetylcholinesterase and Monoamine Oxidases for Alzheimer's and Other Neurological Disorders

  2025cites this paper
• Effects of tianeptine on mTORC1-mediated neuronal autophagy in primary rat hippocampal neurons under nutrient deprivation

  2025cites this paper
• Adenosine A2A receptor modulation affects the development of depressive-like behaviour and dopamine D2 receptor availability in rats exposed to repeated social defeat.

  2025cites this paper
• Analytical Methods for Tetracyclic Antidepressants: A Comprehensive Review

  2024cites this paper
• Advancing past ketamine: emerging glutamatergic compounds for the treatment of depression

  2024cites this paper
• The multifaceted effects of fluoxetine treatment on cognitive functions

  2024cites this paper
• Prefrontal cortex—nucleus reuniens—hippocampus network exhibits sex-differentiated responses to stress and antidepressant treatment in rats

  2024cites this paper
• Psychosocial functioning and its influencing factors in patients with depression post-remission: Implications for assessment and interventions.

  2024cites this paper
• Pharmaceutical Studies on Piperazine-Based Compounds Targeting Serotonin Receptors and Serotonin Reuptake Transporters.

  2024cites this paper
• Serendipity in psychotropic drugs: Unearthing the origins

  2024cites this paper
• Glutamate-Mediated Excitotoxicity in the Pathogenesis and Treatment of Neurodevelopmental and Adult Mental Disorders

  2024cites this paper
• Role of Serotonylation and SERT Posttranslational Modifications in Alzheimer's Disease Pathogenesis

  2024cites this paper
• Dynamic quantitative monitoring of cerebrospinal fluid monoamine neurotransmitter markers during the modeling process of chronic stress‐induced depression in monkeys (Macaca mulatta)

  2024cites this paper
• Depression, an unmet health need in Africa: Understanding the promise of ketamine

  2024cites this paper
• Pathogenesis of depression and the potential for traditional Chinese medicine treatment

  2024cites this paper
• Effects of psychedelics on neurogenesis and broader neuroplasticity: a systematic review

  2024cites this paper
• Embracing variability in the search for biological mechanisms of psychiatric illness.

  2024cites this paper
• Fears Worth Testing Out: A Systematic Review of the Neural Mechanisms of Treatment Outcome for Anxiety-Related Disorders.

  2024cites this paper
• Effects of Imipramine on Anxiety, Depressive-like Behavior and Body Weight Gain in Rats Housed in Overcrowded Conditions

  2024cites this paper
• Evidence for the contribution of vasopressin V1B receptors in the pathophysiology of depression.

  2024cites this paper
• Advancements Exploring Major Depressive Disorder: Insights on Oxidative Stress, Serotonin Metabolism, BDNF, HPA Axis Dysfunction, and Pharmacotherapy Advances

  2024cites this paper
• Resuscitation from Respiratory Arrest Due to Life-Threatening Ventricular Arrhythmias in a Patient with Amitriptyline Intoxication: An Old Problem in a New Era

  2024cites this paper
• A Comprehensive Review of the Pathophysiology of Depression

  2024influential citation
• Targeting monoamine oxidase A: a strategy for inhibiting tumor growth with both immune checkpoint inhibitors and immune modulators

  2024cites this paper
• Cucurbitacin B Exerts Significant Antidepressant-Like Effects in a Chronic Unpredictable Mild Stress Model of Depression: Involvement of the Hippocampal BDNF-TrkB System

  2023cites this paper
• Whole Person Modeling: a transdisciplinary approach to mental health research

  2023cites this paper
• Intersection of Sex and Depression: Pathogenesis, Presentation, and Treatments.

  2023cites this paper
• Connexin 43: An Interface Connecting Neuroinflammation to Depression

  2023cites this paper
• Antidepressants and their metabolites primarily affect lysosomal functions in the marine mussel, Mytilus galloprovincialis.

  2023cites this paper
• Psychiatric genome-wide association study enrichment shows promise for future psychopharmaceutical discoveries

  2023cites this paper
• Pharmacotherapy: Ketamine and Esketamine.

  2023cites this paper
• Electrochemical Chemically Based Sensors and Emerging Enzymatic Biosensors for Antidepressant Drug Detection: A Review

  2023cites this paper
• Verbascoside: A neuroprotective phenylethanoid glycosides with anti-depressive properties.

  2023cites this paper
• Next generation antidepressants with novel mechanisms for treatment resistant depression.

  2023cites this paper
• Life Course Patterns of Prescription Drug Use in the United States.

  2023cites this paper
• Psychotherapy, pharmacotherapy, and their combination in the treatment of major depressive disorder: How well are we making use of available therapies?

  2023cites this paper
• The Economics of Treatment for Depression.

  2023cites this paper
• Expanding the notion of mechanism to further understanding of biopsychosocial disorders? Depression and medically-unexplained pain as cases in point.

  2023cites this paper
• Behind the Curtain: Therapeutic Drug Monitoring of Psychotropic Drugs from a Laboratory Analytical Perspective

  2023cites this paper
• PET imaging of animal models with depressive-like phenotypes

  2023cites this paper
• Mechanism of GW117 antidepressant action: Melatonin receptor-mediated regulation of sleep rhythm.

  2023cites this paper
• The History of Drug Development in Psychiatry: A Lesson in Serendipity.

  2023cites this paper
• The neurobiology of stress: Vulnerability, resilience, and major depression

  2023cites this paper
• The dynamic interaction between symptoms and pharmacological treatment in patients with major depressive disorder: the role of network intervention analysis

  2023cites this paper
• Herbal Interventions as Promising Therapeutics for Alleviating of Depression

  2023cites this paper
• The research progress on related genes affecting depression and their roles in rodent models

  2023cites this paper
• Synthesis, in vitro, and in silico studies of new derivatives of diphenylpiperazine scaffold: A key substructure for MAO inhibition.

  2023cites this paper
• Lactate: a prospective target for therapeutic intervention in psychiatric disease

  2023cites this paper
• Antidepressant- and anxiolytic-like actions of Cajanus cajan seed extract mediated through monoaminergic, nitric oxide-cyclic GMP and GABAergic pathways.

  2023cites this paper
• Circadian Rhythms and Sleep Disorders Associated to Major Depressive Disorder: Pathophysiology and Therapeutic Opportunities.

  2023cites this paper
• Design of an Electrochemical Genosensor for BDNF Gene Polymorphism Sequence Detection Using an Enzymatically Labeled DNA Probe

  2023cites this paper
• Storm on predictive brain: a neurocomputational account of ketamine antidepressant effect.

  2023cites this paper
• Relationship between physical activity and individual mental health after traumatic events: a systematic review

  2023cites this paper
• The possible place for psychedelics in pharmacotherapy of mental disorders

  2023cites this paper
• Direct evidence for the involvement of intestinal reactive oxygen species in the progress of depression via the gut-brain axis.

  2023cites this paper
• Psychedelic phenomenology and the role of affect in psychological transformation

  2023cites this paper
• Neuroinflammation in HIV-associated depression: evidence and future perspectives

  2022cites this paper
• Partial resistance to citalopram in a Wistar-Kyoto rat model of depression: An evaluation using resting-state functional MRI and graph analysis.

  2022cites this paper
• Is the chemical imbalance an ‘urban legend’? An exploration of the status of the serotonin theory of depression in the academic literature

  2022cites this paper
• Experience of antidepressant use and discontinuation: A qualitative synthesis of the evidence

  2022cites this paper
• Effects of escitalopram therapy on functional brain controllability in major depressive disorder.

  2022cites this paper
• Connexin 43: insights into candidate pathological mechanisms of depression and its implications in antidepressant therapy

  2022cites this paper
• Translational Neuropsychopharmacology for Major Depression: Targeting Neurotransmitter Systems

  2022cites this paper
• Ketamine and Other Glutamate Receptor Antagonists As Fast-Actin

  2022cites this paper
• (S)-5-Methylmellein Isolated from an Endogenous Lichen Fungus Rosellinia corticium as a Potent Inhibitor of Human Monoamine Oxidase A

  2022cites this paper
• Anxiolytic and antidepressant-like activities of aqueous extract of Azadirachta indica A. Juss. flower in the stressed rats

  2022cites this paper
• Antidepressive-Like Effect of Aegle marmelos Leaf Extract in Chronic Unpredictable Mild Stress-Induced Depression-Like Behaviour in Rats

  2022cites this paper
• The Interrelation between Oxidative Stress, Depression and Inflammation through the Kynurenine Pathway.

  2022cites this paper
• Development and Clinical Application of Positron Emission Tomography Imaging Agents for Monoamine Oxidase B

  2022cites this paper
• Systematic review of studies using platelet serotonin content to assess bioeffect of serotonin reuptake inhibitors at the serotonin transporter

  2022cites this paper
• Effects of Tibetan medicine metacinnabar (β-HgS) combined with imipramine or sertraline on depression-like symptoms in mice

  2022cites this paper
• Increased Antidepressant/Anxiolytic Prescriptions are Impacted by the Society in Multiple Ways

  2022cites this paper